558 related articles for article (PubMed ID: 27516093)
1. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
[TBL] [Abstract][Full Text] [Related]
2. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.
Xu B; Sun T; Zhang Q; Zhang P; Yuan Z; Jiang Z; Wang X; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Shen K; Yu S; Li H; Tang L; Qiu R;
Ann Oncol; 2021 Feb; 32(2):218-228. PubMed ID: 33188874
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN
J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
[TBL] [Abstract][Full Text] [Related]
7. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
[TBL] [Abstract][Full Text] [Related]
9. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Estévez LG; Batista N; Sánchez-Rovira P; Velasco A; Provencio M; León A; Dómine M; Cruz J; Rodríguez M
Clin Breast Cancer; 2008 Apr; 8(2):149-54. PubMed ID: 18621611
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
11. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
[TBL] [Abstract][Full Text] [Related]
12. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Wang J; Fan Y; Xu B
Cancer Chemother Pharmacol; 2010 Aug; 66(3):597-603. PubMed ID: 20490795
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Sparano JA; Vrdoljak E; Rixe O; Xu B; Manikhas A; Medina C; Da Costa SC; Ro J; Rubio G; Rondinon M; Perez Manga G; Peck R; Poulart V; Conte P
J Clin Oncol; 2010 Jul; 28(20):3256-63. PubMed ID: 20530276
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
Liao M; Jiang Q; Hu H; Han J; She L; Yao L; Ding D; Huang J
J Med Econ; 2019 Jun; 22(6):584-592. PubMed ID: 30808230
[No Abstract] [Full Text] [Related]
15. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
Li T; Guo M; Gradishar WJ; Sparano JA; Perez EA; Wang M; Sledge GW
Breast Cancer Res Treat; 2012 Jul; 134(1):345-52. PubMed ID: 22547107
[TBL] [Abstract][Full Text] [Related]
17. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.
Lv F; Cao J; Liu Z; Wang Z; Zhang J; Zhang S; Wang L; Zhao X; Shao Z; Wang B; Hu X
PLoS One; 2015; 10(3):e0118607. PubMed ID: 25768439
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.
Aogi K; Rai Y; Ito Y; Masuda N; Watanabe J; Horiguchi J; Tokudome T; Takashima S
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1427-33. PubMed ID: 23536163
[TBL] [Abstract][Full Text] [Related]
20. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Fumoleau P; Largillier R; Clippe C; Dièras V; Orfeuvre H; Lesimple T; Culine S; Audhuy B; Serin D; Curé H; Vuillemin E; Morère JF; Montestruc F; Mouri Z; Namer M
Eur J Cancer; 2004 Mar; 40(4):536-42. PubMed ID: 14962720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
